MMI receives FDA approval to expand REMIND microsurgery study

Jul 30, 2026 · Regulatory · MMI · Surgical

The FDA approved an IDE supplement allowing MMI to expand the REMIND Symani study from its initial cohort of up to five patients to the full 15-patient early-feasibility enrolment.

Verified eventMMIJul 30, 2026

Evidence notes

  • The supplement followed FDA review of 30-day safety data from the first patient cohort.
  • REMIND evaluates Symani-enabled microsurgical techniques intended to re-establish deep-cervical lymphatic drainage in patients with Alzheimer's disease and confirmed lymphatic abnormalities.
  • The study remains an early-feasibility investigation; Symani is not FDA-cleared for lymphatic reconstruction for brain disease.

Company context

Surgical-robotics company developing the Symani system for microsurgery and supermicrosurgery.

Links